Jazz to Highlight Narcolepsy and IH Research at AAN 2024
The research includes an oral presentation revealing that individuals with idiopathic hypersomnia experienced higher odds of comorbid conditions, such as cardiovascular disease.
The research includes an oral presentation revealing that individuals with idiopathic hypersomnia experienced higher odds of comorbid conditions, such as cardiovascular disease.
Takeda announced positive results from a phase 2b trial evaluating TAK-861, an oral orexin receptor 2 agonist, in patients with narcolepsy type 1.
The men experienced serious skin reactions and mouth ulcers after taking drugs indicated for narcolepsy. They had been hoping for cognitive enhancement.
In the third quarter, low-sodium Xywav grew 30% year-over-year, despite additional competition, with continued adoption across both narcolepsy and idiopathic hypersomnia
Read MoreThe investigational drug demonstrated a statistically significant and clinically meaningful reduction in excessive daytime sleepiness in adult narcolepsy patients.
Read MoreIn its third-quarter business update, Zevra Therapeutics Inc designated KP1077, its investigational drug in development for idiopathic hypersomnia and narcolepsy, as a pivotal focus area.
Read MoreAxsome Therapeutics reported third-quarter business updates, noting a continued increase in prescriptions for Sunosi and clinical trial progress.
Read MoreHarmony Biosciences reported a 37% increase in net revenue in the third quarter, largely attributed to the growth in patient use of its narcolepsy drug Wakix.
Read MoreCentessa Pharmaceuticals is focused on moving ORX750 through IND-enabling studies, obtaining IND clearance, and initiating clinical development of ORX750, which has shown potential to treat narcolepsy in preclinical studies.
Read MoreAlkermes announced preliminary results from a phase 1 study evaluating ALKS 2680, the company’s investigational orexin-2 receptor agonist in development for the treatment of narcolepsy.
Read MoreJazz Pharmaceuticals announced new data highlighting the importance of low-sodium treatment options to help manage cardiovascular risk in patients with narcolepsy and idiopathic hypersomnia.
Read MoreAt World Sleep 2023, Jazz Pharmaceuticals will spotlight the link between sleep disorders and cardiovascular health through 14 abstracts.
Read MoreIn a small clinical trial, solriamfetol—approved for treating excessive daytime sleepiness caused by narcolepsy or obstructive sleep apnea—was an effective therapy for attention-deficit/hyperactivity disorder in adults.
Read MoreAlkermes plc will present new data on ALKS 2680, an investigational orexin-2 receptor agonist in development for the treatment of narcolepsy, at World Sleep Congress.
Read MoreThe review evaluated all high-sodium oxybates, fixed-dose, and twice-nightly administrations in both oxybate-experienced patients and those who had not undergone prior treatment.
Read MoreOne poster will feature results from the SHARP study, a trial of Sunosi in 59 patients with excessive daytime sleepiness associated with OSA and impaired cognitive function.
Read MoreThe United States Patent and Trademark Office has denied a Petition for Reexamination concerning a patent covering the active ingredient in Wakix (pitolisant).
Read MoreNLS Pharmaceutics issued a letter updating stakeholders on its progress in developing treatments for sleep disorders, which include Mazindol ER for narcolepsy, NLS-4 for idiopathic hypersomnia, and NLS-11 for Kleine-Levin Syndrome.
Read More